FDA Hitting Pause Button More Often on Trials Involving Risky Therapies Such as Gene and Stem Cell Treatments
Wall Street Journal analyzes 10 years of data
The headline in Wall Street Journal said it all this morning:
“FDA Increasingly Halting Human Trials as Companies Pursue Risky, Cutting-Edge Drugs”
The article by Liz Essley Whyte said,
“The Food and Drug Administration (FDA) is pressing pause on drug-company testing of experimental medicines more often, a side effect of the industry’s move into promising…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.